Cefixime
As of the edition of 20 October 2026, Cefixime is a small molecule: marketed, first approved in 1988 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1990
- Kind
- Small molecule
- Brand name
- Suprax
- First approved
- 5 September 1988 (FR)
- Approvals on record
- 7 in 3 regions
- Holder of the most recent approval
- Lupin; 4 holders in all
- Registered trials
- 19, 3 stopped early
- Disease areas
- Infections; Urinary and reproductive; Cancer; Pregnancy and women's health; Chemically induced; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 9 | 8 | 0 | 1 |
| Phase 2 | 4 | 3 | 0 | 0 |
| Phase 3 | 2 | 0 | 1 | 1 |
| Phase 4 | 3 | 1 | 0 | 1 |
| All trials | 19 |